Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodríguez C, Serrano J, Sayas MJ, Martínez-Sánchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Pérez-Simón JA, Herrera P, Barrios M, Noriega-Concepción V, Raposo-Puglia JA, Ayala R, Barragán E, Martínez-Cuadrón D, Amigo ML, López-Lorenzo JL, Lázaro-García A, Guimaraes JE, Colorado M, García-Boyero R, De Rueda-Ciller B, Foncillas-García M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group.
Suárez EU, et al. Among authors: amigo ml.
Ann Hematol. 2024 Aug;103(8):2845-2851. doi: 10.1007/s00277-024-05840-7. Epub 2024 Jun 17.
Ann Hematol. 2024.
PMID: 38884787